UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
(Mark One)
|
☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 30, 2020
OR
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission File Number: 001-39203
1LIFE HEALTHCARE, INC.
(Exact Name of Registrant as Specified in its Charter)
|
Delaware |
76-0707204 |
|
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
|
One Embarcadero Center, Suite 1900 San Francisco, CA 94111 |
94111 |
|
(Address of principal executive offices) |
(Zip Code) |
Registrant’s telephone number, including area code:
(415) 814-0927
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
Common Stock, $0.001 par value |
|
ONEM |
|
The Nasdaq Global Select Market |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
|
|
|
|
|||
|
Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☐ |
|
|
|
|
|
|
|
|
|
Emerging growth company |
|
☒ |
|
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of October 30, 2020, the registrant had 133,012,658 shares of common stock, $0.001 par value per share, outstanding.
|
|
|
Page |
|
PART I. |
|
|
|
Item 1. |
1 |
|
|
|
1 |
|
|
|
2 |
|
|
|
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) |
3 |
|
|
4 |
|
|
|
6 |
|
|
|
Notes to Unaudited Condensed Consolidated Financial Statements (Unaudited) |
7 |
|
Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
23 |
|
Item 3. |
40 |
|
|
Item 4. |
40 |
|
|
|
|
|
|
PART II. |
|
|
|
Item 1. |
42 |
|
|
Item 1A. |
42 |
|
|
Item 2. |
56 |
|
|
Item 3. |
57 |
|
|
Item 4. |
57 |
|
|
Item 5. |
57 |
|
|
Item 6. |
58 |
|
|
59 |
||
Where You Can Find More Information
Investors and others should note that we announce material financial and other information using our investor relations website, press releases, SEC filings and public conference calls and webcasts. We also post supplemental materials on the “Events and Presentations” section of our investor relations website at investor.onemedical.com. Except as specifically noted herein, information on or accessible through our website is not, and will not be deemed to be, a part of this Quarterly Report on Form 10-Q or incorporated by reference into any other filings we may make with the U.S. Securities and Exchange Commission (the “SEC”).
We also use our Facebook, Twitter and LinkedIn accounts as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. The information we post through these social media channels may be deemed material. Accordingly, investors should monitor these accounts, in addition to following our press releases, SEC filings and public conference calls and webcasts. This list may be updated from time to time. The information we post through these channels is not a part of this Quarterly Report on Form 10-Q. These channels may be updated from time to time on our investor relations website.
i
1LIFE HEALTHCARE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands, except share and per share amounts)
(unaudited)
|
|
|
September 30, |
|
|
December 31, |
|
||
|
|
|
2020 |
|
|
2019 |
|
||
|
Assets |
|
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
161,468 |
|
|
$ |
27,390 |
|
|
Short-term marketable securities |
|
|
520,839 |
|
|
|
119,146 |
|
|
Accounts receivable, net |
|
|
52,960 |
|
|
|
33,601 |
|
|
Inventories |
|
|
4,588 |
|
|
|
3,192 |
|
|
Prepaid expenses and other current assets |
|
|
18,936 |
|
|
|
16,708 |
|
|
Total current assets |
|
|
758,791 |
|
|
|
200,037 |
|
|
Restricted cash |
|
|
2,014 |
|
|
|
1,922 |
|
|
Property and equipment, net |
|
|
119,098 |
|
|
|
90,716 |
|
|
Right-of-use assets |
|
|
131,861 |
|
|
|
108,046 |
|
|
Intangible assets, net |
|
|
- |
|
|
|
23 |
|
|
Goodwill |
|
|
21,301 |
|
|
|
21,301 |
|
|
Other assets |
|
|
5,240 |
|
|
|
8,249 |
|
|
Total assets |
|
$ |
1,038,305 |
|
|
$ |
430,294 |
|
|
Liabilities, Redeemable Convertible Preferred Stock and Equity (Deficit) |
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
9,182 |
|
|
$ |
13,853 |
|
|
Accrued expenses |
|
|
36,938 |
|
|
|
24,863 |
|
|
Deferred revenue, current |
|
|
35,624 |
|
|
|
27,024 |
|
|
Operating lease liabilities, current |
|
|
15,962 |
|
|
|
12,575 |
|
|
Notes payable, current |
|
|
- |
|
|
|
3,282 |
|
|
Other current liabilities |
|
|
4,872 |
|
|
|
1,884 |
|
|
Total current liabilities |
|
|
102,578 |
|
|
|
83,481 |
|
|
Operating lease liabilities, non-current |
|
|
146,746 |
|
|
|
120,497 |
|
|
Convertible senior notes |
|
|
237,888 |
|
|
|
- |
|
|
Redeemable convertible preferred stock warrant liability |
|
|
- |
|
|
|
7,220 |
|
|
Deferred revenue, non-current |
|
|
7,590 |
|
|
|
- |
|
|
Other non-current liabilities |
|
|
5,889 |
|
|
|
639 |
|
|
Total liabilities |
|
|
500,691 |
|
|
|
211,837 |
|
|
Commitments and contingencies (Note 14) |
|
|
|
|
|
|
|
|
|
Redeemable convertible preferred stock (Series A, B, C, D, E, F, G, H and I), $0.001 par value; 0 and 89,338,425 shares authorized as of September 30, 2020 and December 31, 2019, respectively; 0 and 86,251,669 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively; aggregate liquidation preference of $0 and $405,585 as of September 30, 2020 and December 31, 2019, respectively |
|
|
- |
|
|
|
402,488 |
|
|
Equity (deficit): |
|
|
|
|
|
|
|
|
|
Common stock, $0.001 par value, 1,000,000,000 and 150,000,000 shares authorized as of September 30, 2020 and December 31, 2019, respectively; 132,545,706 and 18,951,416 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively |
|
|
133 |
|
|
|
19 |
|
|
Additional paid-in capital |
|
|
899,093 |
|
|
|
93,945 |
|
|
Accumulated deficit |
|
|
(361,637 |
) |
|
|
(281,068 |
) |
|
Accumulated other comprehensive income |
|
|
25 |
|
|
|
38 |
|
|
Total stockholders' equity (deficit) attributable to 1Life Healthcare, Inc. stockholders |
|
|
537,614 |
|
|
|
(187,066 |
) |
|
Noncontrolling interest |
|
|
- |
|
|
|
3,035 |
|
|
Total equity (deficit) |
|
|
537,614 |
|
|
|
(184,031 |
) |
|
Total liabilities, redeemable convertible preferred stock and equity (deficit) |
|
$ |
1,038,305 |
|
|
$ |
430,294 |
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands, except share and per share amounts)
(unaudited)
|
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
||||||||||
|
|
|
September 30, |
|
|
September 30, |
|
||||||||||
|
|
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
||||
|
Net revenue |
|
$ |
101,667 |
|
|
$ |
69,629 |
|
|
$ |
258,423 |
|
|
$ |
198,872 |
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of care, exclusive of depreciation and amortization shown separately below |
|
|
58,781 |
|
|
|
41,420 |
|
|
|
163,780 |
|
|
|
118,586 |
|
|
Sales and marketing |
|
|
7,914 |
|
|
|
12,464 |
|
|
|
28,847 |
|
|
|
28,830 |
|
|
General and administrative |
|
|
40,059 |
|
|
|
27,778 |
|
|
|
118,236 |
|
|
|
77,167 |
|
|
Depreciation and amortization |
|
|
5,735 |
|
|
|
3,645 |
|
|
|
16,123 |
|
|
|
9,440 |
|
|
Total operating expenses |
|
|
112,489 |
|
|
|
85,307 |
|
|
|
326,986 |
|
|
|
234,023 |
|
|
Loss from operations |
|
|
(10,822 |
) |
|
|
(15,678 |
) |
|
|
(68,563 |
) |
|
|
(35,151 |
) |
|
Other income (expense), net: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income |
|
|
235 |
|
|
|
1,087 |
|
|
|
1,635 |
|
|
|
3,676 |
|
|
Interest expense |
|
|
(5,647 |
) |
|
|
(107 |
) |
|
|
(7,676 |
) |
|
|
(393 |
) |
|
Change in fair value of redeemable convertible preferred stock warrant liability |
|
|
- |
|
|
|
(890 |
) |
|
|
(6,560 |
) |
|
|
(2,226 |
) |
|
Total other income (expense), net |
|
|
(5,412 |
) |
|
|
90 |
|
|
|
(12,601 |
) |
|
|
1,057 |
|
|
Loss before income taxes |
|
|
(16,234 |
) |
|
|
(15,588 |
) |
|
|
(81,164 |
) |
|
|
(34,094 |
) |
|
Provision for income taxes |
|
|
181 |
|
|
|
57 |
|
|
|
109 |
|
|
|
83 |
|
|
Net loss |
|
|
(16,415 |
) |
|
|
(15,645 |
) |
|
|
(81,273 |
) |
|
|
(34,177 |
) |
|
Less: Net loss attributable to noncontrolling interest |
|
|
- |
|
|
|
(388 |
) |
|
|
(704 |
) |
|
|
(1,049 |
) |
|
Net loss attributable to 1Life Healthcare, Inc. stockholders |
|
$ |
(16,415 |
) |
|
$ |
(15,257 |
) |
|
$ |
(80,569 |
) |
|
$ |
(33,128 |
) |
|
Net loss per share attributable to 1Life Healthcare, Inc. stockholders — basic and diluted |
|
$ |
(0.13 |
) |
|
$ |
(0.82 |
) |
|
$ |
(0.71 |
) |
|
$ |
(1.80 |
) |
|
Weighted average common shares outstanding — basic and diluted |
|
|
128,557,071 |
|
|
|
18,539,935 |
|
|
|
113,253,219 |
|
|
|
18,371,298 |
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Amounts in thousands)
(unaudited)
|
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
||||||||||
|
|
|
September 30, |
|
|
September 30, |
|
||||||||||
|
|
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
||||
|
Net loss |
|
$ |
(16,415 |
) |
|
$ |
(15,645 |
) |
|
$ |
(81,273 |
) |
|
$ |
(34,177 |
) |
|
Other comprehensive loss: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net unrealized gain (loss) on short-term marketable securities |
|
|
(6 |
) |
|
|
(8 |
) |
|
|
(13 |
) |
|
|
59 |
|
|
Comprehensive loss |
|
|
(16,421 |
) |
|
|
(15,653 |
) |
|
|
(81,286 |
) |
|
|
(34,118 |
) |
|
Less: Comprehensive loss attributable to noncontrolling interests |
|
|
- |
|
|
|
(388 |
) |
|
|
(704 |
) |
|
|
(1,049 |
) |
|
Comprehensive loss attributable to 1Life Healthcare, Inc. stockholders |
|
$ |
(16,421 |
) |
|
$ |
(15,265 |
) |
|
$ |
(80,582 |
) |
|
$ |
(33,069 |
) |
The accompanying notes are an integral part of these condensed consolidated financial statements.
3
1LIFE HEALTHCARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND EQUITY (DEFICIT)
(Amounts in thousands, except share amounts)
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders' |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity (Deficit) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Attributable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated |
|
|
to 1Life |
|
|
|
|
|
|
|
|
|
||
|
|
|
Redeemable Convertible |
|
|
|
|
|
|
|
|
|
|
Additional |
|
|
|
|
|
|
Other |
|
|
Healthcare, |
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
Preferred Stock |
|
|
Common Stock |
|
|
Paid-In |
|
|
Accumulated |
|
|
Comprehensive |
|
|
Inc. |
|
|
Noncontrolling |
|
|
Total |
|
||||||||||||||||
|
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Deficit |
|
|
Income (Loss) |
|
|
Stockholders' |
|
|
Interest |
|
|
Equity (Deficit) |
|
||||||||||
|
Balances at December 31, 2018 |
|
|
86,251,669 |
|
|
$ |
402,488 |
|
|
|
18,135,457 |
|
|
$ |
18 |
|
|
$ |
76,029 |
|
|
$ |
(228,449 |
) |
|
$ |
(14 |
) |
|
$ |
(152,416 |
) |
|
$ |
4,176 |
|
|
$ |
(148,240 |
) |
|
Impact of adoption of ASC 606 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(65 |
) |
|
|
|
|
|
|
(65 |
) |
|
|
|
|
|
|
(65 |
) |
|
Exercise of stock options |
|
|
|
|
|
|
|
|
|
|
136,548 |
|
|
|
|
|
|
|
587 |
|
|
|
|
|
|
|
|
|
|
|
587 |
|
|
|
|
|
|
|
587 |
|
|
Stock-based compensation expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,954 |
|
|
|
|
|
|
|
|
|
|
|
2,954 |
|
|
|
|
|
|
|
2,954 |
|
|
Net unrealized gain on short-term marketable securities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31 |
|
|
|
31 |
|
|
|
|
|
|
|
31 |
|
|
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(6,670 |
) |
|
|
|
|
|
|
(6,670 |
) |
|
|
(374 |
) |
|
|
(7,044 |
) |
|
Balances at March 31, 2019 |
|
|
86,251,669 |
|
|
$ |
402,488 |
|
|
|
18,272,005 |
|
|
$ |
18 |
|
|
$ |
79,570 |
|
|
$ |
(235,184 |
) |
|
$ |
17 |
|
|
$ |
(155,579 |
) |
|
$ |
3,802 |
|
|
$ |
(151,777 |
) |
|
Exercise of stock options |
|
|
|
|
|
|
|
|
|
|
182,406 |
|
|
|
|
|
|
|
685 |
|
|
|
|
|
|
|
|
|
|
|
685 |
|
|
|
|
|
|
|
685 |
|
|
Stock-based compensation expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,390 |
|
|
|
|
|
|
|
|
|
|
|
3,390 |
|
|
|
|
|
|
|
3,390 |
|
|
Net unrealized gain on short-term marketable securities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
36 |
|
|
|
36 |
|
|
|
|
|
|
|
36 |
|
|
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(11,201 |
) |
|
|
|
|
|
|
(11,201 |
) |
|
|
(287 |
) |
|
|
(11,488 |
) |
|
Balances at June 30, 2019 |
|
|
86,251,669 |
|
|
$ |
402,488 |
|
|
|
18,454,411 |
|
|
$ |
18 |
|
|
$ |
83,645 |
|
|
$ |
(246,385 |
) |
|
$ |
53 |
|
|
$ |
(162,669 |
) |
|
$ |
3,515 |
|
|
$ |
(159,154 |
) |
|
Exercise of stock options |
|
|
|
|
|
|
|
|
|
|
205,118 |
|
|
|
1 |
|
|
|
676 |
|
|
|
|
|
|
|
|
|
|
|
677 |
|
|
|
|
|
|
|
677 |
|
|
Stock-based compensation expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,786 |
|
|
|
|
|
|
|
|
|
|
|
3,786 |
|
|
|
|
|
|
|
3,786 |
|
|
Net unrealized gain on short-term marketable securities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8 |
) |
|
|
(8 |
) |
|
|
|
|
|
|
(8 |
) |
|
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(15,257 |
) |
|
|
|
|
|
|
(15,257 |
) |
|
|
(388 |
) |
|
|
(15,645 |
) |
|
Balances at September 30, 2019 |
|
|
86,251,669 |
|
|
$ |
402,488 |
|
|
|
18,659,529 |
|
|
$ |
19 |
|
|
$ |
88,107 |
|
|
$ |
(261,642 |
) |
|
$ |
45 |
|
|
$ |
(173,471 |
) |
|
$ |
3,127 |
|
|
$ |
(170,344 |
) |
The accompanying notes are an integral part of these condensed consolidated financial statements.
4
CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND EQUITY (DEFICIT)
(Amounts in thousands, except share amounts)
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders' |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity (Deficit) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Attributable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated |
|
|
to 1Life |
|
|
|
|
|
|
|
|
|
||
|
|
|
Redeemable Convertible |
|
|
|
|
|
|
|
|
|
|
Additional |
|
|
|
|
|
|
Other |
|
|
Healthcare, |
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
Preferred Stock |
|
|
Common Stock |
|
|
Paid-In |
|
|
Accumulated |
|
|
Comprehensive |
|
|
Inc. |
|
|
Noncontrolling |
|
|
Total |
|
||||||||||||||||
|
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Deficit |
|
|
Income (Loss) |
|
|
Stockholders' |
|
|
Interest |
|
|
Equity (Deficit) |
|
||||||||||
|
Balances at December 31, 2019 |
|
|
86,251,669 |
|
|
$ |
402,488 |
|
|
|
18,951,416 |
|
|
$ |
19 |
|
|
$ |
93,945 |
|
|
$ |
(281,068 |
) |
|
$ |
38 |
|
|
$ |
(187,066 |
) |
|
$ |
3,035 |
|
|
$ |
(184,031 |
) |
|
Exercise of redeemable convertible preferred stock warrant |
|
|
5,573 |
|
|
|
76 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
|
|
|
|
|
|
|
- |
|
|
Conversion of redeemable convertible preferred stock into common stock upon closing of initial public offering |
|
|
(86,257,242 |
) |
|
|
(402,564 |
) |
|
|
86,257,242 |
|
|
|
86 |
|
|
|
402,478 |
|
|
|
|
|
|
|
|
|
|
|
402,564 |
|
|
|
|
|
|
|
402,564 |
|
|
Issuance of common stock upon closing of initial public offering, net of issuance costs and underwriting fees of $23,631 |
|
|
|
|
|
|
|
|
|
|
20,125,000 |
|
|
|
20 |
|
|
|
258,099 |
|
|
|
|
|
|
|
|
|
|
|
258,119 |
|
|
|
|
|
|
|
258,119 |
|
|
Fair value adjustment to redeemable convertible preferred stock warrants upon conversion into common stock warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13,740 |
|
|
|
|
|
|
|
|
|
|
|
13,740 |
|
|
|
|
|
|
|
13,740 |
|
|
Exercise of stock options |
|
|
|
|
|
|
|
|
|
|
293,807 |
|
|
|
- |
|
|
|
1,534 |
|
|
|
|
|
|
|
|
|
|
|
1,534 |
|
|
|
|
|
|
|
1,534 |
|
|
Exercise of common stock warrants |
|
|
|
|
|
|
|
|
|
|
11,010 |
|
|
|
- |
|
|
|
73 |
|
|
|
|
|
|
|
|
|
|
|
73 |
|
|
|
|
|
|
|
73 |
|
|
Cashless exercise of common stock warrants |
|
|
|
|
|
|
|
|
|
|
464,297 |
|
|
|
1 |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
1 |
|
|
|
|
|
|
|
1 |
|